Eikon Therapeutics, Inc. · NASDAQ Global Select · priced Feb 5, 2026 · $381M raised · Over $250M
Price since listing
- Hype
- Distribution
- Lock-up window
- Valley
- Accumulation
- Recovery
Volume bars are coloured by lifecycle phase. Markers: lock-up and early release (orange), earnings releases (E), follow-on offerings (F), research signals (rule id and signal; arrow up = buy signal, arrow down = sell or short signal, or sell signal for deals under $50M). Current phase: Valley.
Performance since the IPO
- EIKN
- S&P 500 (SPY)
- Typical IPO over $250m
- Middle 50% of those IPOs
EIKN measured from its offer price; S&P 500 from the first trading day. The typical-IPO line is the median of 340 over $250m IPOs from 2014–2025, by trading day.
Company
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers a…
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Employees
- 384
- Market cap
- $305M
- Website
- eikontx.com
From the prospectus
- Lock-up
- 180 days
- Early release on earnings
- No
- Price-based early release
- No
- Staggered release
- No
- Float sold in IPO
- 39%
- Locked shares per share sold
- 1.5×
- Backed by
- Venture capital
- Lead underwriters
- J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC
- Dual-class shares
- No
- Controlled company
- No
- Foreign private issuer
- No
Extracted from the final prospectus on SEC EDGAR.
Returns vs offer, compared with 135 IPOs over $250m
| Horizon | EIKN | Peer median | Peers below offer |
|---|---|---|---|
| Day 1 | -16.7% | +12.8% | 24% n=135 |
| Day 20 | -19.2% | +11.6% | 30% n=133 |
| Day 60 | -46.2% | +6.3% | 47% n=129 |
| Day 120 | -49.9% | -4.6% | 54% n=106 |
| Day 180 | -54.2% | -4.1% | 52% n=89 |
Research signals
- BuyRule C1: buy signal for 40 sessionsOct 26, 2026 · CapitulationPast signals (652, deals of $50M and over): rose 53% · median +2.1% · dropped 25%+ during the hold 33%backtest
Buy signals passed on returns relative to IPOs of the same year, size and age, most of which fall after listing. A buy signal can beat its peers and still lose money.
- BuyRule T1: buy signal for 60 sessionsJul 7, 2026 · Pre-unlock qualityPast signals (642, deals of $50M and over): rose 47% · median -2.6% · dropped 25%+ during the hold 35%backtest
Buy signals passed on returns relative to IPOs of the same year, size and age, most of which fall after listing. A buy signal can beat its peers and still lose money.
- BuyRule RL: buy signal for 60 sessionsJul 7, 2026 · Pre-unlock risk tierPast signals (329, deals of $50M and over): rose 54% · median +1.3% · dropped 25%+ during the hold 22%backtest
Buy signals passed on returns relative to IPOs of the same year, size and age, most of which fall after listing. A buy signal can beat its peers and still lose money.
Rules frozen as v1; signals dated from Oct 29, 2026 are live, earlier ones show what the frozen rules would have flagged. See methodology.
Past figures cover all 4,312 signals the published frozen v1 rules produce on 2014–2025 IPOs, close to close over each signal's holding period. Returns start at the close of the signal session; signals are published after that close, so the first price available to a reader is the next session's. Only 1,192 of 2,368 operating-company IPOs from those years have usable Yahoo Finance price data; most of the rest no longer trade under their IPO ticker (delisted, acquired or renamed), so the figures probably understate declines. These are hypothetical results, not trades: the rules were selected on these same years with the benefit of hindsight, so the figures likely overstate what live signals will do. The live track record is the real test. Trading costs and borrow fees are not included. Past results do not predict future results.
Research signals only, not investment advice. Lock-up terms come from prospectuses; prices from Yahoo Finance and may be delayed or wrong.